FilingSEC EDGAR8-K
Connect Biopharma Reports Mixed Results in Phase 2 Asthma Trial
· SEC accepted
StagePhase 2
Filing content
The company observed a 66% reduction in treatment failure in its Phase 2 asthma trial but failed to reach statistical significance, and plans to discuss a Phase 3 program with the FDA.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…